ReviewThe Indian journal of surgery2015
Ductal Carcinoma In Situ of the Breast.
Review in The Indian journal of surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Oncological safety of active surveillance for low-risk ductal carcinoma in situ - a systematic review and meta-analysis.Irish journal of medical science · 2023Pooled it
- Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.BJS open · 2022Pooled it
- High-content stimulated Raman histology of human breast cancer.Theranostics · 2024Article
- MiRNA expression deregulation correlates with the Oncotype DXBreast cancer research : BCR · 2022Article
- Monitoring Progression of Ductal Carcinoma In Situ Using Photoacoustics and Contrast-Enhanced Ultrasound.Translational oncology · 2019Article
- The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.Breast cancer (Dove Medical Press) · 2019Article
- The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERα) in breast cancer cells.Breast cancer (Dove Medical Press) · 2017Article
- Effects of Atrial Natriuretic Peptide on p53 and Estrogen Receptor in Breast Cancer Cells.BioResearch open access · 2017Article
- The regulation of steroid receptors by epigallocatechin-3-gallate in breast cancer cells.Breast cancer (Dove Medical Press) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ductal carcinoma in situ (DCIS) of the breast is a potentially invasive neoplasm. Risk factors include high estrogen states such as use of oral contraceptive (OC) pills, nulliparity, advanced age at first birth, and also family history and genetic mutations. The incidence of this usually clinically silent condition has risen in the past few decades due to widespread screening and diagnostic mammography, with final diagnosis confirmed by biopsy. At present, treatment options include total or simple mastectomy or lumpectomy with radiation. Adjuvant therapy includes antiestrogens like tamoxifen and human epidermal growth factor receptor 2 (HER2) suppression therapy. With the latest advances in chemotherapy and better understanding on the pathogenesis of the lesion, it is anticipated that more effective modalities of treatment may soon be available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.